Trials / Conditions / Duct Cell Adenocarcinoma of the Pancreas

Duct Cell Adenocarcinoma of the Pancreas

23 registered clinical trials studyying Duct Cell Adenocarcinoma of the Pancreas.

Status	Trial	Sponsor	Phase
Completed	Stereotactic Radiosurgery and Metformin in Patients With Borderline-Resectable or Locally-Advanced Pancreatic NCT02153450	Case Comprehensive Cancer Center	EARLY_Phase 1
Withdrawn	Dovitinib Lactate, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Tr NCT02048943	Roswell Park Cancer Institute	Phase 1
Completed	Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer NCT02178436	Mohammed Najeeb Al Hallak	Phase 1 / Phase 2
Withdrawn	Dynamic Contrast Enhanced MRI in Patients With Advanced Breast or Pancreatic Cancer With Metastases to the Liv NCT01741597	City of Hope Medical Center	Phase 1
Completed	Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer NCT02047474	Yale University	Phase 2
Completed	Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors or Pancreatic Cancer NCT01924260	Edward Kim	Phase 1
Completed	CPI-613 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer NCT01839981	Wake Forest University Health Sciences	Phase 1
Completed	Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients with Pancreatic NCT01821612	Alliance for Clinical Trials in Oncology	EARLY_Phase 1
Terminated	Chemoradiation and Radiosurgery Boost in Treating Patients With Locally Advance Pancreatic Cancer That May or NCT01739439	Fox Chase Cancer Center	Phase 1
Completed	Ultrasound-Guided Photodynamic Therapy With Photofrin & Gemcitabine for Patients With Locally Advanced Pancrea NCT01770132	John DeWitt	Phase 1
Completed	CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer NCT01835041	Wake Forest University Health Sciences	Phase 1
Completed	Gemcitabine Hydrochloride in Treating Patients With Locally Advanced Pancreatic Cancer NCT01893294	Mayo Clinic	Phase 1
Completed	Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer NCT01666730	Case Comprehensive Cancer Center	Phase 2
Completed	Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Stage III-IV or Recurrent Pancreatic Cancer NCT01473940	Northwestern University	Phase 1
Completed	Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointest NCT01643499	University of Chicago	Phase 1
Completed	Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Can NCT01537107	Mayo Clinic	Phase 1
Completed	Dasatinib and Gemcitabine Hydrochloride or Gemcitabine Hydrochloride Alone in Treating Patients With Pancreati NCT01234935	Translational Oncology Research International	Phase 2
Completed	Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Ca NCT00981162	Roswell Park Cancer Institute	Phase 1
Terminated	Bortezomib and Carboplatin in Treating Patients With Metastatic Pancreatic Cancer NCT00416793	National Cancer Institute (NCI)	Phase 2
Completed	Sunitinib in Treating Patients With Metastatic Pancreatic Cancer That Progressed After First-Line Therapy With NCT00397787	National Cancer Institute (NCI)	Phase 2
Completed	Triapine as First-Line or Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Cancer NCT00085371	National Cancer Institute (NCI)	Phase 2
Completed	Bortezomib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer NCT00052689	National Cancer Institute (NCI)	Phase 2
Completed	Paclitaxel and Bryostatin 1 in Treating Patients With Advanced Pancreatic Cancer NCT00031694	National Cancer Institute (NCI)	Phase 2